CYMA Stock UPDATES Cymabay Therapeutics (CYMA) 6.4500 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cymabay Therapeutics (CYMA) 6.4500 $CYMA

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
Marketwire - Mon Jun 16, 8:02AM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.

CymaBay Therapeutics to Present at Upcoming Conferences
Marketwire - Thu Jun 05, 2:12AM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), today announced that senior management will present an overview of the company at the following upcoming conferences.

CymaBay reports launch of Phase 2b study of arhalofenate in gout patients
M2 - Thu Mar 27, 5:19AM CDT
Biopharmaceutical company CymaBay Therapeutics (OTC BB:CYMA) said on Wednesday that it has randomized the first patient under its Phase 2b clinical trial of arhalofenate for for the treatment of gout, a chronic, progressive rheumatic disease.

CymaBay Initiates Arhalofenate Phase 2b Gout Study
Marketwire - Wed Mar 26, 3:21PM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing therapies addressing unmet medical needs in metabolic disease, today announced that it has randomized the first patient in a Phase 2b clinical trial of arhalofenate (MBX-102). Arhalofenate is a dual acting product candidate for the treatment of gout that is targeted to lower serum uric acid (sUA) and reduce the incidence of flares.

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
Marketwire - Mon Mar 03, 8:02AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
Marketwire - Tue Feb 25, 8:05AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Mixed Dyslipidemia - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/85sdh6/mixed) has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Mixed Dyslipidemia. - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mixed Dyslipidemia Overview Therapeutics Development Pipeline Products for Mixed Dyslipidemia - Overview Pipeline Products for Mixed Dyslipidemia - Comparative Analysis Mixed Dyslipidemia - Therapeutics under Development by Companies Mixed Dyslipidemia - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Mixed Dyslipidemia - Products under Development by Companies Mixed Dyslipidemia - Companies Involved in Therapeutics Development Mixed Dyslipidemia - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles evolocumab - Drug Profile Product Description Mechanism of Action R&D Progress bococizumab - Drug Profile Product Description Mechanism of Action R&D Progress INSUPR-001 DR - Drug Profile Product Description Mechanism of Action R&D Progress MBX-8025 - Drug Profile Product Description Mechanism of Action R&D Progress PRC-4016 - Drug Profile Product Description Mechanism of Action R&D Progress CAT-2003 - Drug Profile Product Description Mechanism of Action R&D Progress MAT-9001 - Drug Profile Product Description Mechanism of Action R&D Progress Mixed Dyslipidemia - Recent Pipeline Updates Mixed Dyslipidemia - Dormant Projects Mixed Dyslipidemia - Discontinued Products Mixed Dyslipidemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Pfizer Inc. Pronova BioPharma ASA Intas Pharmaceuticals Ltd. Catabasis Pharmaceuticals, Inc. Matinas BioPharma, Inc. CymaBay Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/85sdh6/mixed About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
Marketwire - Fri Jan 24, 8:00AM CST
CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 114

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 7

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 172

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 215

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 66

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 207

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 26

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading